STAAR SURGICAL CO Form 8-K		
September 20, 2017		
UNITED STATES		
SECURITIES AND EXCHANGE COMMISSI	ION	
WASHINGTON, DC 20549		
TODA O V		
FORM 8-K		
CURRENT REPORT  Purguent to Section 13 or 15(d) of the Securities	og Evolvange A et of 1024	
Pursuant to Section 13 or 15(d) of the Securities	es Exchange Act of 1954	
Date of report (Date of earliest event reported)	· Sentember 20 2017	
Date of report (Date of earliest event reported)	. september 20, 2017	
STAAR Surgical Company		
(Exact Name of Registrant as Specified in Cha	rter)	
Delaware	0-11634	95-3797439
(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(I.R.S. Employer Identification No.)
1911 Walker Ave., Monrovia, California (Address of Principal Executive Offices)		91016 ( <b>Zip Code</b> )

# Edgar Filing: STAAR SURGICAL CO - Form 8-K

Not Applicable
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions ( <i>see</i> General Instruction A.2. below):
"Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
"Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
"Pre-commencement communication pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
"Pre-commencement communication pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1 933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).
Emerging growth company "
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. "

## Edgar Filing: STAAR SURGICAL CO - Form 8-K

## Item 7.01 Regulation FD Disclosure.

Representatives of STAAR Surgical Company will give presentations to investors commencing on September 20, 2017. A copy of the slide presentation they will use in their presentations is furnished as Exhibit 99.1 to this Report, and is incorporated herein by this reference.

The information furnished herewith pursuant to Item 7.01 of this Current Report, including Exhibit 99.1, shall not be deemed to be "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section. The information in Item 7.01 of this Current Report shall not be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date of this Current Report, regardless of any general incorporation language in the filing.

#### **Item 9.01 Financial Statements and Exhibits**

(d) Exhibits

# **Exhibit No. Description**

99.1 Slide Presentation dated September 2017.

# **SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

STAAR Surgical Company

# Edgar Filing: STAAR SURGICAL CO - Form 8-K

September 20, 2017 By:/s/ Caren Mason
Caren Mason
President and Chief Executive Officer